在动脉高血压中诊断和治疗静脉功能障碍
1Servicio de Cardiología, Hospital Moisés Broggi, Sant Joan Despí, Barcelona, Spain.
Hipertension y riesgo vascular
|July 26, 2025
概括
腹筋功能障碍,在高血压中很常见,损害了心脏的填充,并与心力衰竭有关. 新的治疗方法对这种情况显示出希望.
科学领域:
- 心脏病学 心脏病学
- 高血压研究 高血压研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 扩张性功能障碍 (DD) 损害了心室的放松和填充.
- 左心室DD在高血压中很普遍,增加了发病率和死亡率,特别是心力衰竭与保留的喷射分数 (HFpEF).
- 病理生理学涉及心脏结构/功能变化,神经激素激活和血管硬.
研究的目的:
- 审查高血压 (HTN) 中DD的病理生理机制.
- 讨论高血压患者DD的诊断方法.
- 探索DD和HFpEF的新兴和潜在治疗方法.
主要方法:
- 关于病理生理机制的文献综述.
- 对诊断标准的分析,主要是心声回声.
- 评估最近的治疗进展,包括SGLT2抑制剂,GLP-1受体激动剂和芬.
主要成果:
- 高血压显著导致DD的发展.
- 心声图仍然是DD诊断的基石.
- 新的药理学药剂显示出在控制DD和HFpEF方面的潜力.
结论:
- 高血压中的DD是一种复杂的疾病,具有重大临床影响.
- 早期诊断和有针对性的治疗对于改善结果至关重要.
- 新兴疗法为DD和HFpEF患者提供了新的希望.
关键词:
扩张性功能障碍 扩张性功能障碍腹腔功能障碍 腹腔功能障碍心声回声扫描 (Echocardiography) 是一种心声回声扫描.通过心脏生态图 (Ecocardiografía) 进行心脏表达.在高血压的情况下,高血压.在高血压的高血压.更多相关视频
相关概念视频
Aortic Regurgitation III: Medical Management
44
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
44
Heart Failure V: Medical Management
25
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
25
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
35
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
35
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35
Cardiomyopathy V: Interprofessional Care
34
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
34
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
510
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510


